CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immunomedics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immunomedics, Inc.
300 the American Rd
Phone: (973) 605-8200p:973 605-8200 Morris Plains, NJ  07950-2460  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 10/23/2020.
This company ceased filing statements with the SEC on 11/2/2020.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202012/31/2019YesYes-YesYes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board BehzadAghazadeh 2/25/2019 3/1/2017
Chief Financial Officer, Chief Business Officer UsamaMalik 45 2/23/2019
Chief Human Resource Officer Kurt J.Andrews 50 9/1/2018 9/1/2018
11 additional Officers and Directors records available in full report.

Business Names
Business Name
IBC Pharmaceuticals, Inc.
IMMU
Immunomedics GmbH

General Information
Number of Employees: 366 (As of 12/31/2019)
Outstanding Shares: 231,156,742 (As of 9/9/2020)
Shareholders: 328
Stock Exchange: NASD
Federal Tax Id: 611009366
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 30, 2023